Following a priority review of these data, the FDA approved revumenib as a treatment for KMT2A-rearranged acute leukemias in the relapsed or refractory setting while awaiting the final analysis for the NPM1-mutated AML subset (Table 1). This evidence concerns the gene KMT2A and acute leukemia.